Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD01 in Bladder Cancer
NCT07359235Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of KD01 in bladder cancer (3 arms), sponsored by Tongji Hospital. Primary endpoints: Serious Adverse Events and Adverse Events at 2 years and Maximum Tolerated Dose at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
KD01
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT07359235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359235.